Allergenimmuntherapie bei atopischer Dermatitis

Traidl, Stephan; Werfel, Thomas

doi:10.1007/s00105-021-04909-y

Cited by 7 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…По данным мировых исследований, наиболее важную роль в патогенезе АтД играет IgE-зависимая сенсибилизация к аллергенам клещей домашней пыли, пыльцевым и пищевым аллергенам [12][13][14] . Аллергенспецифическая иммунотерапия (АСИТ) является единственным патогенетическим методом лечения, который может предотвратить прогрессирование заболевания и развитие атопического марша .…”

Section: обоснованиеunclassified

The experience with subcutaneous allergen-specific immunotherapy with pollen allergens in patients with atopic dermatitis

Elisyutina,

Litovkina,

Smolnikov

et al. 2024

Russian Journal of Allergy

View full text Add to dashboard Cite

BACKGROUND: AIMS: determination of the clinical significance of sensitization to pollen allergens in AD, determination of indications for ASIT with pollen allergens and assessment of the effectiveness and safety of this method in AD patients. MATERIALS AND METHODS: A comparative controlled study to evaluate the efficacy of SCIT with birch pollen allergens or grass in 78 AD patients were conducted. A single course of SCIT with tree pollen allergens was administered to 33 patients, and grass pollen allergens were administered to 21 patients with AD. The comparison group – AD patients on standard therapy – 24 patients. The primary endpoints were based on the reduction in the severity of AD symptoms, based on the absolute and relative number of patients who achieved SCORAD score by 75% and IGA 1/0. RESULTS: In patients received SCIT with tree pollen allergens, SCORAD 50 achieved 26%, 33%, 47% and SCORAD 75 achieved 10%, 20% and 33% after 16, 32 and 52 weeks, respectively. In patients received SCIT with grass pollen allergens, SCORAD 50 reached 31%, 40%, 58% and SCORAD 75 - 14%, 28% and 43% after 16, 32 and 52 weeks, respectively. In the comparison group: SCORAD 50 reached 24%, 32%, 37% and SCORAD 75 - 13%, 22% and 26% after 16, 32 and 52 weeks, respectively. Similar results were obtained when studying the IGA. In all study groups, an improvement of the DIQI index by 4 or more points in 12%, 25% and 37% of patients receiving one course of scASIT with tree pollen allergens, in 14%, 28% and 43% in patients after 16, 32 and 52 weeks, respectively. However, the number of such patients in the comparison group was significantly lower: 13%, 22% and 26%, respectively. CONCLUSIONS: ASIT is an effective way to treat AD patients, provided there is proven sensitization to pollen allergens

show abstract

Section: обоснованиеunclassified